Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

被引：1
|
作者：
Dieter Koeberle
Beat Thuerlimann
机构：
[1] Kantonsspital,Department of Internal Medicine, Division Oncology/Hematology
来源：
Breast Cancer Research and Treatment | 2008年 / 112卷 / 2期
关键词：
D O I：
10.1007/s10549-007-9858-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：387 / 387
相关论文
共 50 条
  • [21] Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Meredith M Regan
    Karen N Price
    Anita Giobbie-Hurder
    Beat Thürlimann
    Richard D Gelber
    Breast Cancer Research, 13
  • [22] Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
    Viale, G.
    Regan, M. M.
    Dell'Orto, P.
    Mastropasqua, M. G.
    Rasmussen, B. B.
    MacGrogan, G.
    Braye, S.
    Orosz, Z.
    Giobbie-Hurder, A.
    Neven, P.
    Knox, F.
    Oehlschlegel, C.
    Thuerlimann, B.
    Coates, A. S.
    Goldhirsch, A.
    CANCER RESEARCH, 2009, 69 (24) : 504S - 504S
  • [23] Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer:: The BIG 1-98 trial
    Crivellari, Diana
    Sun, Zhuoxin
    Coates, Alan S.
    Price, Karen N.
    Thuerlimann, Beat
    Mouridsen, Henning
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert J.
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Colleoni, Marco
    Lang, Istvan
    Del Mastro, Lucia
    Gladieff, Laurence
    Rabaglio, Manuela
    Smith, Ian E.
    Chirgwin, Jacquie H.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 1972 - 1979
  • [24] Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
    Tusquets Trias de Bes, Ignasi
    Tormo, Sonia Servitja
    Mestres, Joan Albanell
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (01) : 1 - 10
  • [25] Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer
    Rasmussen, B. B.
    Regan, M. M.
    Lykkesfeldt, A. E.
    Dell'Orto, P.
    Del Curto, B.
    Henriksen, K. L.
    Mastropasqua, M. G.
    Thurlimann, B.
    Viale, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
    Mouridsen, H. T.
    Giobbie-Hurder, A.
    Mauriac, L.
    Paridaens, R.
    Colleoni, M.
    Thuerlimann, B.
    Forbes, J. F.
    Gelber, R. D.
    Wardley, A.
    Smith, I
    Price, K. N.
    Coates, A.
    Goldhirsch, A.
    CANCER RESEARCH, 2009, 69 (02) : 66S - 67S
  • [27] Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
    Viale, G
    Regan, M
    Dell'Orto, P
    Del Curto, B
    Braye, S
    Orosz, Z
    Brown, R
    Olszewski, WP
    Knox, F
    Oehlschlegel, C
    Thürlimann, B
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S13 - S14
  • [28] Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
    Rabaglio, M.
    Sun, Z.
    Price, K. N.
    Castiglione-Gertsch, M.
    Hawle, H.
    Thurlimann, B.
    Mouridsen, H.
    Campone, M.
    Forbes, J. F.
    Paridaens, R. J.
    Colleoni, M.
    Pienkowski, T.
    Nogaret, J. -M.
    Lang, I.
    Smith, I.
    Gelber, R. D.
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2009, 20 (09) : 1489 - 1498
  • [29] BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
    BREAST, 2005, 14 : S3 - S3
  • [30] Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen:: Safety analysis of BIG 1-98 trial
    Mouridsen, Henning
    Keshaviah, Aparna
    Coates, Alan S.
    Rabaglio, Manuela
    Castiglione-Gertsch, Monica
    Sun, Zhuoxin
    Thuerlimann, Beat
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert
    Gelber, Richard D.
    Colleoni, Marco
    Smith, Ian
    Price, Karen N.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) : 5715 - 5722
12345